Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMECBWN)

Drug Name
Riluzole Drug Info
Synonyms
Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine
Indication
Disease Entry ICD 11 Status REF
Amyotrophic lateral sclerosis 8B60.0 Approved [1]
Therapeutic Class
Anticonvulsants
Cross-matching ID
PubChem CID
5070
ChEBI ID
CHEMBL744
CAS Number
CAS 1744-22-5
TTD Drug ID
DMECBWN
VARIDT Drug ID
DR00205
INTEDE Drug ID
DR1425
ACDINA Drug ID
D00595

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [10]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [11]
Lacosamide DMVM6QR Convulsion 8A68.Z Approved [12]
Tolperisone DMA2GHJ Muscle spasm MB47.3 Approved [13]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [14]
Eslicarbazepine DMZREFQ Seizure disorder 8A6Z Approved [12]
Oxcarbazepine DM5PU6O Epilepsy 8A60-8A68 Approved [15]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [16]
QX-314 DMAV2FM Pain MG30-MG3Z Terminated [17]
PD-32577 DMBA15J Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [19]
Methotrexate DM2TEOL Anterior urethra cancer Approved [20]
Folic Acid DMEMBJC Colorectal carcinoma Approved [21]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [22]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [23]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [24]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [24]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [26]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [28]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [29]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [31]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [32]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [33]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [34]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [35]
Verapamil DMA7PEW Angina pectoris BA40 Approved [36]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [38]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [41]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [43]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [44]
Metronidazole DMTIVEN Abscess Approved [45]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [46]
Ethanol DMDRQZU Chronic pain MG30 Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [48]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [49]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [50]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [51]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [35]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [52]
Estrone DM5T6US Acne vulgaris ED80 Approved [53]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [54]
Riboflavin DM8YMWE Acne vulgaris ED80 Approved [55]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [8]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [8]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [57]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [58]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [59]
Etidronic acid DM1XHYJ Bone Paget disease Approved [8]
Tiaprofenic acid DM23D7J Osteoarthritis FA00-FA05 Approved [8]
Bromperidol DM24XYQ Schizophrenia 6A20 Approved [8]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [60]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [63]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [62]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Pyrazinamide DM4IF32 Meningeal tuberculosis Approved [65]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [66]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [67]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [62]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [68]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kallikrein-2 (KLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [70]
Testosterone DM7HUNW Hot flushes GA30 Approved [71]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [72]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [73]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [74]
Dutasteride DMQ4TJK Benign prostatic hyperplasia GA90 Approved [75]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [76]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [77]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [78]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [79]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Blocker [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) Main DME DEJGDUW CP1A2_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Gene/Protein Processing [7]
Kallikrein-2 (KLK2) OT9RE37R KLK2_HUMAN Gene/Protein Processing [7]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [8]
Utrophin OT7TZ637 UTRN_HUMAN Gene/Protein Processing [9]
X-box-binding protein 1 OTJYCREE XBP1_HUMAN Gene/Protein Processing [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2326).
2 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
3 Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
4 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
5 Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997 Sep;282(3):1465-72.
6 Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3.
7 Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. Prostate. 2019 Feb;79(2):140-150. doi: 10.1002/pros.23719. Epub 2018 Oct 2.
8 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
9 Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One. 2011;6(10):e26169. doi: 10.1371/journal.pone.0026169. Epub 2011 Oct 20.
10 Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
11 The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
12 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
13 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
14 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
15 Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
16 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
17 Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
18 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
19 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
20 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
21 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
22 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
23 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
24 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
25 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
26 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
27 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
28 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
29 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
30 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
31 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
32 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
33 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
34 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
35 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
36 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
37 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
38 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
39 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
40 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
41 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
42 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
43 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
44 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
45 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
46 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
47 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
48 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
49 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
50 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
51 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
52 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
53 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
54 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
55 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
56 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
57 Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
58 Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
59 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
60 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
61 Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
62 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
63 Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
64 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
65 Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2-ATF4-CHOP pathway. Toxicology. 2017 Mar 1;378:65-75. doi: 10.1016/j.tox.2017.01.002. Epub 2017 Jan 4.
66 Glucosamine-induced endoplasmic reticulum stress attenuates apolipoprotein B100 synthesis via PERK signaling. J Lipid Res. 2009 Sep;50(9):1814-23. doi: 10.1194/jlr.M800343-JLR200. Epub 2009 Apr 21.
67 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
68 Arsenic trioxide initiates ER stress responses, perturbs calcium signalling and promotes apoptosis in human lens epithelial cells. Exp Eye Res. 2007 Dec;85(6):825-35. doi: 10.1016/j.exer.2007.08.018. Epub 2007 Aug 29.
69 Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
70 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
71 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem. 2002 Dec 13;277(50):48366-71. doi: 10.1074/jbc.M209074200. Epub 2002 Oct 9.
72 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
73 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
74 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
75 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
76 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
77 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
78 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11.
79 Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.